Merck Announces Phase 3 KEYNOTE-522 Trial Met its Overall …
WEBMay 28, 2024 · KEYTRUDA® (pembrolizumab) is the first and only immunotherapy-based regimen to show a statistically significant improvement in OS as pre-operative (neoadjuvant) treatment with chemotherapy and then as a single agent after surgery (adjuvant) compared to pre-operative chemotherapy in patients with high-risk early-stage TNBC.
Ten-Year Data for Merck’s KEYTRUDA® (pembrolizumab) …
WEBSep 15, 2024 · KEYTRUDA demonstrated a sustained OS benefit, reducing the risk of death by 29% (HR=0.71 [95% CI, 0.60-0.85]). At 10 years, KEYTRUDA more than doubled the median OS compared to ipilimumab (32.7 ...
Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy …
WEBApr 16, 2023 · The one-year OS rate was 52% for the KEYTRUDA regimen versus 44% for chemotherapy alone; the two-year OS rates were 24.9% versus 18.1%, respectively. The OS results were generally consistent across subgroups.
KEYTRUDA® (pembrolizumab) Significantly Improved Overall …
WEBNov 1, 2023 · KEYTRUDA is the first therapy to show a statistically significant improvement in OS as adjuvant therapy in patients with RCC at a higher risk of recurrence following nephrectomy. New OS results build on the significant disease-free survival benefit previously reported from the KEYNOTE-564 trial.
KEYTRUDA® (pembrolizumab) - Official Site
WEBKEYTRUDA is a prescription medicine used to treat a kind of uterine cancer called advanced endometrial carcinoma. KEYTRUDA may be used with the chemotherapy medicines carboplatin and paclitaxel, and then KEYTRUDA may be used alone, in adults: when your cancer has spread (advanced), or; if your cancer has returned. KEYTRUDA may be used alone in ...
Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell …
WEBApr 16, 2018 · Pembrolizumab (Keytruda, Merck), nivolumab (Opdivo, Bristol-Myers Squibb), and atezolizumab (Tecentriq, Genentech) are approved as second-line therapy.
FDA approves pembrolizumab combination for the first-line …
WEBOn October 13,2021, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) in combination with chemotherapy, with or without bevacizumab, for patients with persistent,...
Pembrolizumab plus Chemotherapy in Advanced Endometrial …
WEBMar 27, 2023 · In patients with advanced or recurrent endometrial cancer, the addition of pembrolizumab to standard chemotherapy resulted in significantly longer progression-free survival than with chemotherapy...
Pembrolizumab plus Chemotherapy in Advanced Triple-Negative …
WEBJul 20, 2022 · Pembrolizumab monotherapy has shown durable antitumor activity in advanced triple-negative breast cancer, 6-9 particularly as first-line therapy, with improved clinical responses observed among...
KEYNOTE-024 and KEYNOTE-042 - First-line Monotherapy for …
WEBKEYTRUDA, in combination with pemetrexed and platinum chemotherapy, is indicated for the first-line treatment of patients with metastatic nonsquamous non–small cell lung cancer (NSCLC), with no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumor aberrations.
- Some results have been removed
Skip to content